Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona RI, Girgis S, Miao X, Uhlar CM, Chastain K, Garfall AL.
Touzeau C, et al. Among authors: martin tg.
Blood. 2024 Dec 5;144(23):2375-2388. doi: 10.1182/blood.2023023616.
Blood. 2024.
PMID: 39172760
Clinical Trial.